-
Context Therapeutics NASDAQ:CNTX Context Therapeutics Inc., is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA.
Location: 3675 Market Street, Suite 200, Pennsylvania, 19104, United States | Website: contexttherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
66.46M
Cash
101.5M
Avg Qtr Burn
-4.601M
Short % of Float
2.62%
Insider Ownership
1.45%
Institutional Own.
76.40%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-95 Details Solid tumor/s | Phase 1 Initiation | |
CTIM-76 Details Solid tumor/s, Testicular cancer, Cervical cancer, Ovarian cancer | Phase 1 Initiation | |
ONA-XR Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer | Failed Discontinued | |
ONA-XR Details Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s | Failed Discontinued | |
ONA-XR Details Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer | Failed Discontinued |